Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 73 Publications

13 Customer Reviews

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Three MET amplified (Hs746t, SNU-5 and MKN45) and two non-amplified cell lines (MKN74 and NUGC-4) were incubated with or without 100nM crizotinib 24 hours, and total protein was extracted using RIPA lysis buffer. Total lysates were then analyzed by immunoblotting using anti-phospho-MET, anti-total-MET, and β-actin antibodies.

    Oncotarget, 2017, 8(31):51675-51687. Crizotinib (PF-02341066) purchased from Selleck.

    Viability of Ba/F3 cells stably expressing DCTN1-ALK or EML4-ALK cDNAs after treatment with crizotinib (C). Ba/F3 cells transduced with lentiviral cDNA or empty vector were subjected to the assay, and the number of cells was counted at 72 hours.

    Oncologist, 2017, 22(2):158-164. Crizotinib (PF-02341066) purchased from Selleck.

  • Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
Targets
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 MX3DfZRwfG:6aXOgRZN{[Xl? M4ns[|Q5KGh? M3jxOmROW09? Mk\oR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDGNVE4PExibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCwMlYzKM7:TR?= MUSyNVU4OjV6OR?=
BAF3 MoHJR5l1d3SxeHnjJGF{e2G7 MUC0PEBp MWrEUXNQ M{DE[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugUFEyQT[PIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNk4zKM7:TR?= M3y4b|IyPTd{NUi5
BAF3 NH63TmREgXSxdH;4bYMhSXO|YYm= NXHvTYNHPDhiaB?= M{\BW2ROW09? NXzh[ZNsS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIFXNUFQuSUyNIIfpeIghUUN3MDDv[kAxNjJ6IN88US=> NFfwWnczOTV5MkW4PS=>
Kelly NVnkeG5HS3m2b4TvfIlkKEG|c3H5 MXjEUXNQ MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDL[YxtgSClZXzsd{BmgHC{ZYPzbY5oKEGOSzDGNVE4PExibYX0ZY51KHerdHigTWM2OCCxZjCwMlQzKM7:TR?= NGDOPHozOTV5MkW4PS=>
SH-SY5Y NUjsZpR1S3m2b4TvfIlkKEG|c3H5 NEP0[4JFVVOR M3S1SmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNJNVO\NWmgZ4VtdHNiZYjwdoV{e2mwZzDBUGshTjFzN{TMJI12fGGwdDD3bZRpKEmFNUCgc4YhOC53MzFOwG0> MUWyNVU4OjV6OR?=
SMS-KCN NWCzNJJzS3m2b4TvfIlkKEG|c3H5 Mkf6SG1UVw>? MkHKR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV21UNUuFTjDj[YxteyCneIDy[ZN{cW6pIFHMT{BTOTJ5NWGgcZV1[W62IIfpeIghUUN3MDDv[kAxNjlzIN88US=> M{HyVFIyPTd{NUi5
BAF3 NWDq[o1RS3m2b4TvfIlkKEG|c3H5 M{jjUVQ5KGh? M4TrTGROW09? NFf2cWlEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiVHXsMWFNUyC5aYToJGlEPTBib3[gNE4yQSEQvF2= NVr2R5pSOjF3N{K1PFk>
3T3 MnPRSpVv[3Srb36gRZN{[Xl? MUmxJIg> MVTEUXNQ Mk[yTY5pcWKrdHnvckBw\iCUT16gZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEig{txO NGWzfXgzOThzMkSxOC=>
3T3-E NX3pOG9CTnWwY4Tpc44hSXO|YYm= Ml\6NUBp NUjGZldHTE2VTx?= MV;Jcohq[mm2aX;uJI9nKFSLRUKgZZN{\XO|ZXSg[5Jwf3SqIH\hZ5Rwei2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvPDR6IN88US=> MmOwNlE5OTJ2MUS=
A549 NF3tcG5McW6jc3WgRZN{[Xl? NF\nPJUyKGh? NUXWPIxPTE2VTx?= NHTqbGVKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IHOtUWVVKGurbnHz[UBmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBJT0ZvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByODFOwG0> MVqyNVgyOjRzNB?=
BAF3-BCL M3:5ZWZ2dmO2aX;uJGF{e2G7 MX[xJIg> NYTmTZJnTE2VTx?= NV7XO3pPUW6qaXLpeIlwdiCxZjDBRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEGuNVU6KM7:TR?= NVzxZmYzOjF6MUK0NVQ>
HEK293 MnOzSpVv[3Srb36gRZN{[Xl? MV:xJIg> M4f2V2ROW09? MW\Jcohq[mm2aX;uJI9nKEG[TDDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5{OUSg{txO NHfSOoozOThzMkSxOC=>
HEK293 MorBSpVv[3Srb36gRZN{[Xl? NVTJeXdqOSCq MkHNSG1UVw>? NG\wTGVKdmirYnn0bY9vKG:oIFnSJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iB{Lki4O{DPxE1? M3SwUVIyQDF{NEG0
Jurkat MYDGeY5kfGmxbjDBd5NigQ>? M2rBXlEhcA>? MWnEUXNQ MVTJcohq[mm2aX;uJI9nKEyFSzDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOi55NEGg{txO MmHxNlE5OTJ2MUS=
KARPAS299 NVniU|RXU2mwYYPlJGF{e2G7 NW\Rd|luOSCq Ml7BSG1UVw>? NXnlToVSUW6qaXLpeIlwdiCxZjDBUGsh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFIh|ryP NYPGSIJ6OjF6MUK0NVQ>
PAE Mn3VSpVv[3Srb36gRZN{[Xl? NGPYNIEyKGh? M{DFN2ROW09? Mle1TY5pcWKrdHnvckBw\iCWUlvCJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkO5PUDPxE1? NHKzNFczOThzMkSxOC=>
BAF3 M{DzOWZ2dmO2aX;uJGF{e2G7 M1\Jc|IuOyCm MmLmSG1UVw>? MlfpTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiaX7zeYxqdiC{ZXPldJRweiCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEvPjR|IN88US=> MnvVNlM4PDJ{NUK=
KARPAS299 NITKSo9EgXSxdH;4bYMhSXO|YYm= MknZNk0{KGR? MXjEUXNQ MnLKTWM2OD1yLkC2OFIh|ryP MnTFNlM4PDJ{NUK=
EBC1 NXjwWG5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vFN|czKGh? MYDEUXNQ MYPJR|UxRTBwMEKzJO69VQ>? M4DSd|I{QTl|M{K4
HCT116 MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXq3NkBp NUm2dFhMTE2VTx?= NGGySGdKSzVyPUG0MlgzKM7:TR?= NXTBWHJuOjN7OUOzNlg>
MCF7 NV\mfZZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTzOG5ZPzJiaB?= MojaSG1UVw>? MnO2TWM2OD17LkW4JO69VQ>? MYWyN|k6OzN{OB?=
MDA-MB-231 MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjRNoZlPzJiaB?= NHTJSmVFVVOR NYrGUW56UUN3ME2xNE45KM7:TR?= M1fvOVI{QTl|M{K4
MKN45 M2Dtbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[3NkBp MW\EUXNQ NYrrZnhjUUN3ME2wMlAyOyEQvF2= M3nrOVI{QTl|M{K4
NCI-H441 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLafYtVPzJiaB?= M3PvSGROW09? NGL5Z3NKSzVyPUG3MlI2KM7:TR?= M{LaXVI{QTl|M{K4
NCI-H661 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFi3PYs4OiCq MkDoSG1UVw>? MUTJR|UxRTFzLkS3JO69VQ>? M{TJV|I{QTl|M{K4
SK-MEL-28 NHLld3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\GT5U4OiCq NXLtS2xUTE2VTx?= MoDUTWM2OD1zMD65O{DPxE1? MYeyN|k6OzN{OB?=
SKOV3 NED0[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvuRoI4OiCq NIHyRYFFVVOR MUjJR|UxRTF{Lki1JO69VQ>? MknTNlM6QTN|Mki=
SNU5 MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nTUVczKGh? MYTEUXNQ NUHEVVNFUUN3ME2wMlAyPiEQvF2= NEXZT24zOzl7M{OyPC=>
NCI-H2228 NUfWZmFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vURVczKGh? MljpSG1UVw>? MnfhTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvOTF6IN88US=> NFvxVXkzPDR|MkmwPS=>
NCI-H3122 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVG3NkBp NXXZNolsTE2VTx?= MUDJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4yODhizszN M4nFblI1PDN{OUC5
NCI-H3122 NIG0fnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLQWFVmPzJiaB?= NV7DPXFZTE2VTx?= MlzxTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCDTFugS|EzPjmDIH31eIFvfCC5aYToJGlEPTBib3[gNE43OjNizszN NGjyT2QzPDR|MkmwPS=>
NCI-H3122 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIi4SI44OiCq NGLtPHBFVVOR NXSzUHZrUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gUmNKNUh|MUKyJINmdGy|IHjhdoJwemmwZzDBUGshVDFzOU\NJI12fGGwdDD3bZRpKEmFNUCgc4YhOC56M{ig{txO MkHxNlQ1OzJ7MEm=
NIH-3T3 MX7LbY5ie2ViQYPzZZk> NF7zdosyKGh? M4DIT2ROW09? Ml7DTY5pcWKrdHnvckBw\iCqdX3hckB4cWymIIT5dIUhTU2OND3meZNm\CCDTFug[ZhxemW|c3XkJIF{e2W|c3XkJIF{KHCqb4PwbI9zgWyjdHXkJGFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1? NEXnS4ozPDR|MkmwPS=>
NIH-3T3 M4W0bmtqdmG|ZTDBd5NigQ>? MWKxJIg> MmPmSG1UVw>? M3fweWlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugS|EzPjmDIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwNkC1JO69VQ>? NIDZTmMzPDR|MkmwPS=>
NIH-3T3 NFzmOI1McW6jc3WgRZN{[Xl? NYXxPGkzOSCq MWTEUXNQ NV7lZXc3UW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BUOTJyNmmgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD62NlYh|ryP NYPSPHByOjR2M{K5NFk>
NIH-3T3 NIjGVXpMcW6jc3WgRZN{[Xl? NFOwPXIyKGh? NInmdYpFVVOR MWnJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFyxNVk3VSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjh2MzFOwG0> MlLsNlQ1OzJ7MEm=
NIH-3T3 M3zFOmtqdmG|ZTDBd5NigQ>? M1\IbVEhcA>? M{i0U2ROW09? MUfJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFyxNVUzWiCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAyNjB{NjFOwG0> M3\TfFI1PDN{OUC5
BAF3 M4fJWWZ2dmO2aX;uJGF{e2G7 MXS3NkBp NEjB[GtFVVOR MlzkTY5pcWKrdHnvckBw\iCQUF2vRWxMKHS{YX7z[oVkfGWmIHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODVzIN88US=> MnS0NlQ1Pjh4M{K=
BAF3 M3TxUGN6fG:2b4jpZ{BCe3OjeR?= NHnXd4s4OiCq MmfVSG1UVw>? M{Lyb2lEPTB;MD65PEDPxE1? MVKyOFQ3QDZ|Mh?=
NIH-3T3 MWfLbY5ie2ViQYPzZZk> NFzhbGUyKGh? NUDvUndtUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BHOTF5NFygcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD6xOlUh|ryP MVGyOFgyQTFzNh?=
NIH-3T3 NIr4dYxMcW6jc3WgRZN{[Xl? M3z3bVEhcA>? NWTNWWRRUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BEOTF3NmmgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD60O|gh|ryP NY\hUGFrOjR6MUmxNVY>
NIH-3T3 MVzLbY5ie2ViQYPzZZk> NUjweIw2OSCq MmO3TY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDHNVIxOlJibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOS5zNEig{txO NHrv[pczPDhzOUGxOi=>
NIH-3T3 M3LtZWtqdmG|ZTDBd5NigQ>? NX7wT5FPOSCq MmryTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzCxNVUyXGmwczDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iB|LkCzPUDPxE1? M3;sSFI1QDF7MUG2
KARPAS299 M{TTSWtqdmG|ZTDBd5NigQ>? NHTQZ206OCCvaX6= NY\5WW8zTE2VTx?= MkXTTY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJJBpd3OyaH;yfYxifGmxbjDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO MkD3NlQ6ODB5NUC=
MKN 45 MXXLbY5ie2ViQYPzZZk> NVniO|hYOSCq NVTGXFliTE2VTx?= MnXVTY5pcWKrdHnvckBw\iClLV3leEBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO NEnJWZMzPDlyMEe1NC=>
A549 M1TKe2N6fG:2b4jpZ{BCe3OjeR?= NY\sfVY2PDhiaB?= NVTiNmJVTE2VTx?= M{[wXWlEPTBib3[gOE4xQDRizszN MWeyOFkxODh|MB?=
NCI-H1975 MV;DfZRwfG:6aXOgRZN{[Xl? MYi0PEBp NUD1SIR1TE2VTx?= M{PU[mlEPTBib3[gO{42PTFizszN M1nlOVI1QTByOEOw
NCI-H1993 MmH6R5l1d3SxeHnjJGF{e2G7 M3XDSVQ5KGh? MWPEUXNQ MX3JR|UxKG:oIECuNFYyKM7:TR?= MYWyOFkxODh|MB?=
NCI-H1993 MXLBdI91d3OrczDBd5NigQ>? NUPCbGN5OSEQvF2= NFHJVYUzPCCq M4nmTGROW09? MWXkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m| NVvMXWZqOjR7MEC4N|A>
NIH-3T3 NVL0VotPS3m2b4TvfIlkKEG|c3H5 NYTUPYc1PDhiaB?= MoOySG1UVw>? NYHLWpdxUUN3MDDv[kAxNjN4NDFOwG0> M1LlNVI1QTByOEOw
EBC1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;OUGk4OiCq NXy0fJpRTE2VTx?= NGi0TY5KSzVyIH;mJFAvODB4OTFOwG0> NGfrTIQzPDlyMEizNS=>
KARPAS299 NEjKNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXj[|Q4OiCq M3KzbmROW09? NYDIVm5UUUN3MDDv[kAxNjJizszN Moq2NlQ6ODB6M{G=
NB1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFryNGhKSzVyPUmxMlk5KG6P Ml7yV2FPT0WU
NCI-SNU-5 NGTX[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj6TWM2OD1zMEWuO|Uhdk1? NVz3OFgyW0GQR1XS
SR NYH6[Jd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljYTWM2OD1zMk[uN|Ehdk1? Mn;NV2FPT0WU
SF539 NV71b21LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnDVFRKSzVyPUKwOE4zPCCwTR?= M{PhXHNCVkeHUh?=
SU-DHL-1 M2\XPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\qTWM2OD1|M{[uPFIhdk1? MkjDV2FPT0WU
SCC-3 MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS4eGFKSzVyPUO1Ok44PiCwTR?= MV3TRW5ITVJ?
DEL MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PLbmlEPTB;M{[5Mlkhdk1? NVK3cZgyW0GQR1XS
CTV-1 M1:5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHxTWM2OD13OU[uOFghdk1? MUXTRW5ITVJ?
EM-2 NVzQN|hkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTZyMT6zOEBvVQ>? M4LtVXNCVkeHUh?=
MHH-CALL-2 MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:2TWM2OD14OEKuOVchdk1? NHO5VZFUSU6JRWK=
KM12 MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorhTWM2OD15ME[uPUBvVQ>? NGTtWGhUSU6JRWK=
KINGS-1 M1r3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DNW2lEPTB;N{S5Mlc2KG6P M1;zc3NCVkeHUh?=
MEG-01 Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPNV3NKSzVyPUi1O{43PiCwTR?= MWrTRW5ITVJ?
BV-173 NWHmN21ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwMEW5PVch|ryP NGLwOGRUSU6JRWK=
LAMA-84 M2jibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTFwM{iyPFIh|ryP NFvMRmNUSU6JRWK=
KARPAS-299 M1XhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFwNEC4OlEh|ryP NYTFdpZSW0GQR1XS
K-562 MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nESGlEPTB;MT63NlI3QSEQvF2= M4rDdnNCVkeHUh?=
SK-LMS-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\PTWM2OD1zLke2PFY4KM7:TR?= MoD2V2FPT0WU
MOLT-16 M4PObmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjhN5ZKSzVyPUGuPVU2PzVizszN NVPYRoc1W0GQR1XS
CMK NH7DPIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTFwOU[xOVkh|ryP MXnTRW5ITVJ?
ST486 NGezOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHXTWM2OD1{LkSzNFc{KM7:TR?= MVzTRW5ITVJ?
CI-1 NX;2OXl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq2VZZvUUN3ME2yMlQ6PjV7IN88US=> NF\LSGVUSU6JRWK=
KP-N-RT-BM-1 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJwN{CxNlIh|ryP NHfQW|NUSU6JRWK=
ALL-PO MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XsSGlEPTB;Mz6xPFIxPyEQvF2= MUHTRW5ITVJ?
KS-1 NGjVTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTNwMkGyNlUh|ryP MXvTRW5ITVJ?
Becker NX;le|BYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlGyTWM2OD12LkKzPVMh|ryP NV\VNJlOW0GQR1XS
GDM-1 NUT3dpQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jXOGlEPTB;ND6yOFYyPyEQvF2= M4PNenNCVkeHUh?=
BC-1 NYPaOoVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTRwNEmyO|ch|ryP MmGzV2FPT0WU
NB14 NXG4SYtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTRwOEO1NlQh|ryP MUDTRW5ITVJ?
NOS-1 M4\iVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jpd2lEPTB;NT6zN|g4PCEQvF2= NFvuNXFUSU6JRWK=
MZ1-PC M3nUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDRTWM2OD13LkiyNVUyKM7:TR?= NIrKbGtUSU6JRWK=
A498 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrLXmRFUUN3ME22MlA5PDd|IN88US=> MVTTRW5ITVJ?
EW-16 M3j0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml33TWM2OD14LkO3O|c{KM7:TR?= M1rzOnNCVkeHUh?=
NALM-6 M2DxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTZwNkizPFch|ryP MUXTRW5ITVJ?
EB-3 MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPIXo9RUUN3ME23MlA4OjN|IN88US=> NGTuclRUSU6JRWK=
697 NI\PdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTlwMkSzNlkh|ryP NVvSbXQ{W0GQR1XS
Ramos-2G6-4C10 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXny[HM{UUN3ME25MlU6QDR{IN88US=> MVrTRW5ITVJ?
KNS-81-FD MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\DTWM2OD17Lk[5OlU{KM7:TR?= M3rjOnNCVkeHUh?=
HUTU-80 NFzuOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfRTWM2OD17Lke0OlQzKM7:TR?= M{PRfnNCVkeHUh?=
LS-411N NYLNdo9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTFyLkC1Olch|ryP M{DKOnNCVkeHUh?=
RPMI-8402 NY\jWpc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFyLkGxOkDPxE1? MmnmV2FPT0WU
KU812 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS2ZXZGUUN3ME2xNE4zQTlzIN88US=> NYrGV29bW0GQR1XS
EW-1 NVjBfoNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFyLkS0NlUh|ryP MkK0V2FPT0WU
HC-1 NWPHbodZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\vTWM2OD1zMD60PFQ1KM7:TR?= M1zTfXNCVkeHUh?=
NB69 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[2WmRKSzVyPUGwMlUxPDNizszN M4fMRnNCVkeHUh?=
MFH-ino MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzQTWM2OD1zMD64N|A{KM7:TR?= MYfTRW5ITVJ?
CCRF-CEM M4LIb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT0TWM2OD1zMT61PVch|ryP M1;HVHNCVkeHUh?=
SK-N-DZ NV[zb5BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF{LkC0N|Yh|ryP MXrTRW5ITVJ?
NCI-H720 M2rrTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF{LkG3NFUh|ryP M3njZ3NCVkeHUh?=
HCC1187 Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnvbGJKSzVyPUGyMlIxPDFizszN NUn3bpB7W0GQR1XS
IST-SL2 Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF{LkS4O|Ih|ryP MlLFV2FPT0WU
KE-37 MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;qSXZ[UUN3ME2xNk44QTZ4IN88US=> NWn3XYE3W0GQR1XS
HCC1599 NE\MVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHMN5ZwUUN3ME2xNk46ODZ7IN88US=> M2TYUnNCVkeHUh?=
A4-Fuk MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n2emlEPTB;MUKuPVU5PiEQvF2= NHzGOWRUSU6JRWK=
NKM-1 NHT4PI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LHWmlEPTB;MUOuNlkzPSEQvF2= NWfzbHlTW0GQR1XS
BE-13 M3;pSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrufHJKSzVyPUGzMlc6QDlizszN MVvTRW5ITVJ?
MV-4-11 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[2cnhDUUN3ME2xOE4xOzJ2IN88US=> Mkf4V2FPT0WU
OPM-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTF2LkSwPFUh|ryP NGThU3dUSU6JRWK=
KARPAS-422 MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF2LkWxNlYh|ryP MVrTRW5ITVJ?
RPMI-8226 M324N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTF2Lki5NVUh|ryP M2jKRXNCVkeHUh?=
KARPAS-45 NFTWWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF3Lke3NVYh|ryP MW\TRW5ITVJ?
SK-PN-DW NGjmUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknZTWM2OD1zNT64OlMyKM7:TR?= MUjTRW5ITVJ?
LC-2 M1fpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHZVoZKSzVyPUG2MlE2ODZizszN M{jTOHNCVkeHUh?=
NCI-H1648 NXXZO2RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;RN41KSzVyPUG2MlI2PCEQvF2= M{HvW3NCVkeHUh?=
RL95-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TXeWlEPTB;MU[uN|k4QCEQvF2= MYXTRW5ITVJ?
KNS-42 NX\FXnNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrlcYZ2UUN3ME2xOk44Ojd2IN88US=> MV;TRW5ITVJ?
RPMI-6666 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljpTWM2OD1zNj65NlEyKM7:TR?= NVeyepBWW0GQR1XS
SIG-M5 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;aWJRKSzVyPUG3MlE6ODNizszN MYjTRW5ITVJ?
VA-ES-BJ M3O5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnqdGRKSzVyPUG3Mlc1PTFizszN MlvsV2FPT0WU
MONO-MAC-6 M1zXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fucWlEPTB;MUeuPVMyOiEQvF2= NInIc|NUSU6JRWK=
LAN-6 NGT2WplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTZb4xqUUN3ME2xPE44PTV5IN88US=> NWHwUpJUW0GQR1XS
A388 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzPTWM2OD1zOT6zNFU6KM7:TR?= MkL6V2FPT0WU
SK-NEP-1 Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJyLkKxN|Ih|ryP M4fpfnNCVkeHUh?=
TE-10 NFTKU|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXtPXYxUUN3ME2yNE42OjJzIN88US=> M3L1dnNCVkeHUh?=
HL-60 M1vlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Xk[mlEPTB;MkCuPVA6QSEQvF2= Mny4V2FPT0WU
MC116 M1zaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TDb2lEPTB;MkGuO|IzOSEQvF2= M{fzOHNCVkeHUh?=
SW962 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJzLke5NVUh|ryP NFLKT4xUSU6JRWK=
NOMO-1 MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPpc5ZEUUN3ME2yNk43PTZ2IN88US=> NEfwTJpUSU6JRWK=
CTB-1 MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJ{Lki2O|Eh|ryP NGrocppUSU6JRWK=
MRK-nu-1 Ml3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\nR2lEPTB;MkKuPVA4PCEQvF2= NXLLNldJW0GQR1XS
GR-ST M1XENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJ|Lke2JO69VQ>? M2XuUnNCVkeHUh?=
HH MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJ2LkCwN{DPxE1? NVr1VIh[W0GQR1XS
NCI-H1963 NV;CdXd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO4WINtUUN3ME2yOE4xPzh{IN88US=> Mk\VV2FPT0WU
QIMR-WIL NVzuZZVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi0NGYzUUN3ME2yOE45Pzd{IN88US=> NHTXfodUSU6JRWK=
CGTH-W-1 NW\MfmdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DabWlEPTB;MkWuNFczOyEQvF2= NXmzeIU{W0GQR1XS
LP-1 NUHSSItMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nSTWlEPTB;MkWuOlU2OSEQvF2= Mo\0V2FPT0WU
NCI-H748 NH3TN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XYUWlEPTB;Mk[uOVE{PyEQvF2= MUXTRW5ITVJ?
PF-382 NFG3U2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLrPJR5UUN3ME2yO{4zOjJ|IN88US=> NXf5fWptW0GQR1XS
ATN-1 NYrvblc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjkVJdKSzVyPUK3MlM4OzJizszN M{LiU3NCVkeHUh?=
L-540 NIfQfIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LuWmlEPTB;MkeuOlQ2QSEQvF2= MknyV2FPT0WU
LXF-289 NVvNS|FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEK5e5VKSzVyPUK3Mlc2OTlizszN M4G4WnNCVkeHUh?=
LS-513 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEP3eG9KSzVyPUK4MlE5ODdizszN MnLhV2FPT0WU
NCI-H1581 MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH35bW1KSzVyPUOwMlM6PzZizszN MkXUV2FPT0WU
ES6 NF75TGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTNyLk[4PVkh|ryP NEL3[YRUSU6JRWK=
SW982 MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvjfYtKSzVyPUOwMlg2PjZizszN MYXTRW5ITVJ?
DOHH-2 Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLVT2hsUUN3ME2zNU42QDl|IN88US=> M{nKRnNCVkeHUh?=
DB MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;5TWM2OD1|Mz65OFMyKM7:TR?= MnHoV2FPT0WU
MPP-89 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX5dXJKSzVyPUO0MlE4PTZizszN MUXTRW5ITVJ?
LB831-BLC MmnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v0dWlEPTB;M{SuOVE5PCEQvF2= MlX0V2FPT0WU
NB5 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PYUGlEPTB;M{SuPFU{PSEQvF2= M36zXHNCVkeHUh?=
GB-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTN3LkC0Olkh|ryP NG\hS5RUSU6JRWK=
TE-15 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXFW3VKSzVyPUO1MlIzOzhizszN MnO0V2FPT0WU
LC4-1 M4XEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTrdINKSzVyPUO1MlM5PDdizszN NHGycIdUSU6JRWK=
NCI-H747 NVrXVVcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\ROlFKSzVyPUO2MlE{PjlizszN NETW[Y5USU6JRWK=
NTERA-S-cl-D1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33Oe2lEPTB;M{iuO|M1PyEQvF2= M1zQdnNCVkeHUh?=
SK-MM-2 NETX[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLlTWM2OD12MD6xNVQ3KM7:TR?= NES0VJlUSU6JRWK=
TGW M{HXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT5TWM2OD12MT6wOVY{KM7:TR?= MWnTRW5ITVJ?
ONS-76 NYridXFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTR{LkS4PFMh|ryP MUjTRW5ITVJ?
CPC-N NYrMO3JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\QTWM2OD12Mj65PVcyKM7:TR?= M3:3XXNCVkeHUh?=
ES4 MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTR2LkSxOVMh|ryP NHvCNmVUSU6JRWK=
Daudi M4r6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\nc2lEPTB;NEWuNFgzPyEQvF2= M1PmNXNCVkeHUh?=
MOLT-4 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTR3LkC4OVMh|ryP MkXVV2FPT0WU
HT-144 MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLRTWM2OD12Nj63NlYh|ryP Mn3xV2FPT0WU
SW872 Mmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTR6LkG5N|Mh|ryP NX;McFJnW0GQR1XS
D-283MED M3zsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\EfmlEPTB;NEiuN|U1OiEQvF2= MV;TRW5ITVJ?
NCI-H2126 M1LlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK2N|hKSzVyPUS4Mlg1PzZizszN M4HnRXNCVkeHUh?=
NCI-SNU-16 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzV[IExUUN3ME20PU4zOTR|IN88US=> NVK4TZFbW0GQR1XS
CESS M1Tzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTR7LkWwPFgh|ryP Mn\zV2FPT0WU
A101D NF\uOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPiNFRKSzVyPUS5Mlk4OzZizszN NWnHTlQ6W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

Protocol

Kinase Assay:

[1]

+ Expand

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:

[1]

+ Expand
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method:

    Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231
  • Formulation: --
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+dd H2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34
Formula

C21H22Cl2FN5O

CAS No. 877399-52-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03126916 Recruiting Childhood Ganglioneuroblastoma|Childhood Neuroblastoma|INRG Stage L2|INRG Stage M|INRG Stage MS|NMYC Gene Amplification|Recurrent Neuroblastoma Children''s Oncology Group|National Cancer Institute (NCI) May 9 2018 Phase 3
NCT01979536 Recruiting Anaplastic Large Cell Lymphoma ALK-Positive|Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma|CD30-Positive Neoplastic Cells Present National Cancer Institute (NCI) November 8 2013 Phase 2
NCT02040870 Completed Non-Small Cell Lung Cancer Novartis Pharmaceuticals|Novartis March 7 2014 Phase 1|Phase 2
NCT01531361 Active not recruiting Advanced Malignant Neoplasm|BRAF Gene Mutation|Metastatic Malignant Neoplasm|Recurrent Malignant Neoplasm|Refractory Malignant Neoplasm M.D. Anderson Cancer Center|National Cancer Institute (NCI) February 6 2012 Phase 1
NCT02761057 Recruiting Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma National Cancer Institute (NCI) April 5 2016 Phase 2
NCT02094573 Active not recruiting Carcinoma Non-Small-Cell Lung Ariad Pharmaceuticals June 4 2014 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • Answer:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID